



European Reference Network

for rare or low prevalence complex diseases

❖ **Network**

Endocrine Conditions
(Endo-ERN)
Adult Cancers
(ERN EURACAN)

Ihre Nachricht vom:
Ihr Zeichen:

Bitte bei Antwort angeben:
Unser Zeichen:
MF/

Telefon: (09 31) 2 01 – 39 200
Telefax: (09 31) 2 01 – 639 200
Email: fassnacht_m@ukw.de

Würzburg, Nov 2021

EYES Research Observership Programme (R.O.P)

Translational research in the field of adrenal and pituitary tumors

Endocrine tumors are one of the main research topics of the Division of Endocrinology and Diabetes at the University Hospital of Würzburg since many years. Our basic/translational lab team that would host the Early Career Investigators is currently composed of 17 people encompassing 6 post-docs and senior researchers, 3 PhD students, and 8 technicians. Furthermore, this team is closely connected with our clinical research team.

Here, a list of some **research topics**, we are currently working on:

- improving the diagnostic power of plasma and urinary steroid profiling by LC-MS/MS for adrenal tumors
- establishment of prognostic and predictive marker in adrenocortical carcinoma (e.g. mutational profiling, cfDNA, etc.)
- understanding the interaction of glucocorticoids and immune cells in adrenocortical carcinoma
- search for potential treatment targets in adrenocortical carcinoma (e.g. by exome and whole genome sequencing)
- defining the role of immune cell infiltration in pheochromocytoma
- establishment of theranostic concepts for adrenal tumors
- deciphering the molecular pathogenesis of Cushing's disease

Techniques

We routinely use a large array of techniques and approaches that the intern will be able to familiarize with. These include but are not limited to:

- cell culture (with a variety of adrenal cell lines, primary human adrenal cells and immune cells), both in 2D and 3 D models (e.g. spheroids)
- proliferation and cell viability assays

**LEHRSTUHL
ENDOKRINOLOGIE –
DIABETOLOGIE
ZIM – Zentrum für Innere Medizin**

Leiter:
Prof. Dr. M. Fassnacht
Tel.: (09 31) 2 01 - 39 200
Fax: (09 31) 2 01 - 639 200

Stellv.Leiterin:
Frau Prof. Dr. S. Hahner
Tel.: (09 31) 2 01 - 39 201

Leiterin der Stoffwechsel- und Diabetesambulanz Oberärztin:
Frau Dr. A.-C. Koschker
Tel.: (09 31) 2 01 - 39 200

Oberarzt
Dr. U. Dischinger
Tel.: (09 31) 2 01 - 39 200

Endokrinolog. Schwerpunkt-Station
M31-Volhard
Arztzimmer:
Tel.: (09 31) 2 01 - 43 114
Fax: (09 31) 2 01 - 643 114

Endokrinologische Ambulanz
Tel.: (09 31) 2 01 - 39 777
Fax: (09 31) 2 01 - 60 39126

Stoffwechsel- und Diabetes-Ambulanz
Tel.: (09 31) 2 01 - 39 777
Fax: (09 31) 2 01 - 60 39212

Adipositas-Ambulanz
Tel.: (09 31) 2 01 - 39 777
Fax: (09 31) 2 01 - 60 39212

Spezialambulanz Endokrine Tumoren
Tel.: (09 31) 2 01 - 39 717
Fax: (09 31) 2 01 - 639 716

Endokrinologisches Labor
Tel.: (09 31) 2 01 - 39 220
Fax: (09 31) 2 01 - 639 220

Diabetesschulungszentrum
European Training Center in
Endocrinology, Diabetes and
Metabolism (U.E.M.S.)

Tel.: (09 31) 2 01-0 (Zentrale)
www.medizin1.ukw.de

- immunohistochemistry and immunofluorescence
- DNA, RNA- and protein extraction
- RT-qPCR
- RNAscope mRNA in situ hybridisation
- flow cytometry
- LC-MS/MS for steroid analyses (metabolite/precursor)-, metabolomics, plasma metanephrines, salivary cortisol/cortisol, therapeutic drug monitoring
- immunoassay for steroid measurements
- combining lab data from tumor material with patient outcome data (e.g. Kaplan Meier curves, Cox regression analyses etc.)

Contact persons:

Martin Fassnacht (fassnacht_m@ukw.de)
Silviu Sbiera (sbiera_s@ukw.de)
Barbara Altieri (altieri_b@ukw.de)
Laura-Sophie Landwehr (landwehr_l@ukw.de)
Max Kurlbaum (Kurlbaum_m1@ukw.de)

Selected publications

- Beuschlein F*, Fassnacht M*, Assié G*, Calebiro D*, Stratakis CA, Osswald A, Ronchi CL, Wieland T, Sbiera S, Faucz FR, Schaak K, Schmittfull A, Schwarzmayr T, Barreau O, Vezzosi D, Rizk-Rabbin M, Zabel U, Szarek E, Salpea P, Forlino A, Vetro A, Zuffardi O, Kisker C, Diener S, Meitinger T, Lohse MJ, Reincke M, Bertherat J, Strom TM, Allolio B. 2014 Constitutive Activation of PRKACA in Adrenal Cushing's Syndrome. *N Engl J Med* 370(11):1019-28
- Reincke M, Sbiera S, Hayakawa A, Theodoropoulou M, Osswald A, Beuschlein F, Meitinger T, Mizuno-Yamasaki E, Kawaguchi K, Saeki Y, Tanaka K, Wieland T, Graf E, Saeger W, Ronchi CL, Allolio B, Buchfelder M, Strom TM, Fassnacht M*, Komada M*. 2015 Mutations in the deubiquitinase gene USP8 cause Cushing's disease. *Nat Genet*. 47(1):31-8
- Laufs V, Altieri B, Sbiera S, Kircher S, Steinhauer S, Beuschlein F, Quinkler M, Willenberg HS, Rosenwald A, Fassnacht M, Ronchi CL 2018 ERCC1 as predictive biomarker to platinum-based chemotherapy in adrenocortical carcinomas. *Eur J Endocrinol*. 178(2):183-190
- Lippert J, Appenzeller S, Liang R, Sbiera S, Kircher S, Altieri B, Nanda I, Weigand I, Gehrig A, Steinhauer S, Riemsens RJM, Rosenwald A, Müller CR, Kroiss M, Rost S, Fassnacht M, Ronchi CL. 2018 Targeted molecular analysis in adrenocortical carcinomas: a strategy towards improved personalized prognostication. *J Clin Endocrinol Metab*. 103(12):4511-4523
- Heinze B, Fuss CT, Mulatero P, Beuschlein F, Reincke M, Mustafa M, Schirbel A, Deutschbein T, Williams TA, Rhayem Y, Quinkler M, Rayes N, Monticone S, Wild V, Gomez-Sanchez CE, Reis AC, Petersenn S, Wester HJ, Kropf S, Fassnacht M, Lang K, Herrmann K, Buck AK, Bluemel C, Hahner S. 2018 Targeting CXCR4 (CXC Chemokine Receptor Type 4) for Molecular Imaging of Aldosterone-Producing Adenoma. *Hypertension*. 71(2):317-325
- Sbiera S, Kendl S, Weigand I, Sbiera I, Fassnacht M, Kroiss M. 2019 Hsp90 inhibition in adrenocortical carcinoma: Limited drug synergism with mitotane. *Mol Cell Endocrinol*. 480:36-41.
- Schweitzer S, Kunz M, Kurlbaum M, Vey J, Kendl S, Deutschbein T, Hahner S, Fassnacht M, Dandekar T, Kroiss M. 2019 Plasma steroid metabolome profiling for the diagnosis of adrenocortical carcinoma. *Eur J Endocrinol*. 180(2):117-12
- Sbiera S, Perez-Rivas LG, Taranets L, Weigand I, Flitsch J, Graf E, Monoranu CM, Saeger W, Hagel C, Honegger J, Assié G, Hermus AR, Stalla GK, Herterich S, Ronchi CL, Deutschbein T, Reincke M, Strom TM, Popov N, Theodoropoulou M, Fassnacht M 2019 Driver mutations in USP8 wild type Cushing's disease. *Neuro Oncol*. 21(10):1273-1283
- Weigand I, Schreiner J, Röhrig F, Sun N, Landwehr LS, Urlaub H, Kendl S, Kiseljak-Vassiliades K, Wierman ME, Angeli JPF, Walch A, Sbiera S, Fassnacht M, Kroiss M. 2020. Active steroid hormone synthesis renders adrenocortical cells highly susceptible to type II ferroptosis induction. *Cell Death Dis*. 2020 Mar 17;11(3):192. doi: 10.1038/s41419-020-2385-4.

- Altieri B, Sbiera S, Herterich S, De Francia S, Della Casa S, Calabrese A, Pontecorvi A, Quinkler M, Kienitz T, Mannelli M, Canu L, Angelousi A, Chortis V, Kroiss M, Terzolo M, Fassnacht M, Ronchi CL. Effects of Germline CYP2W1*6 and CYP2B6*6 Single Nucleotide Polymorphisms on Mitotane Treatment in Adrenocortical Carcinoma: A Multicenter ENSAT Study. *Cancers (Basel)*. 2020 Feb 4;12(2). 359. doi: 10.3390/cancers12020359.
- Liang R, Weigand I, Lippert J, Kircher S, Altieri B, Steinhauer S, Hantel C, Rost S, Rosenwald A, Kroiss M, Fassnacht M, Sbiera S, Ronchi CL. 2020. Targeted Gene Expression Profile Reveals CDK4 as Therapeutic Target for Selected Patients With Adrenocortical Carcinoma. *Front Endocrinol (Lausanne)*. 2020 Apr 16;11:219. doi: 10.3389/fendo.2020.00219. eCollection 2020
- Kurlbaum M, Sbiera S, Kendl S, Fassnacht M, Kroiss M. 2020. Steroidogenesis in the NCI-H295 Cell Line Model is Strongly Affected By Culture Conditions and Substrain. *Exp Clin Endocrinol Diabetes*. 2020 May 12. doi: 10.1055/a-1169-5951. Online ahead of print.
- Landwehr LS, Altieri B, Schreiner J, Sbiera I, Weigand I, Kroiss M, Fassnacht M, Sbiera S. 2020. Interplay between glucocorticoids and tumor-infiltrating lymphocytes on the prognosis of adrenocortical carcinoma. *J Immunother Cancer*. 2020 May;8(1):e000469.
- Weigand I, Ronchi CL, Vanselow JT, Bathon K, Lenz K, Herterich S, Schlosser A, Kroiss M, Fassnacht M, Calebiro D, Sbiera S. PKA α subunit mutation triggers caspase-dependent RII β subunit degradation via Ser114 phosphorylation. *Sci Adv*. 2021 Feb 19;7(8):eabd4176
- Landwehr LS, Schreiner J, Appenzeller S, Kircher S, Herterich S, Sbiera S, Fassnacht M, Kroiss M, Weigand I. A novel patient-derived cell line of adrenocortical carcinoma shows a pathogenic role of germline MUTYH mutation and high tumour mutational burden. *Eur J Endocrinol*. 2021 May 4;184(6):823-835
- Vogg N, Kurlbaum M, Deutschbein T, Gräsl B, Fassnacht M, Kroiss M. 2021. Method-Specific Cortisol and Dexamethasone Thresholds Increase Clinical Specificity of the Dexamethasone Suppression Test for Cushing Syndrome. *Clin Chem*. 2021 Jul 6;67(7):998-1007
- Sbiera I, Kircher S, Altieri B, Fassnacht M, Kroiss M, Sbiera S. 2021. Epithelial and Mesenchymal Markers in Adrenocortical Tissues: How Mesenchymal Are Adrenocortical Tissues? *Cancers (Basel)*. 2021 Apr 6;13(7):1736